Managing Uncertainty In Drug Value: Outcomes-Based Contracting Supports Value-Based Pricing

Prices for drugs should reflect their value. If price and value become disconnected, efforts to produce new therapies won’t focus on the treatments with the highest net benefit for patients and payers. A challenge arises when the value of a drug is uncertain. Durable drug therapies such as gene therapies have benefits that might last a lifetime, but clinical trial data at launch may be limited with regard to both duration and target population.
Read more...

;